Advancing potential colorectal (colon) cancer treatment options
Learn about Pfizer’s clinical research into a potential targeted therapy for colorectal cancer.
Colorectal cancer, also called colon cancer, is the second leading cause of cancer death in the United States. Pfizer is currently conducting a clinical trial with a focus on colorectal cancer that:
- is advanced or metastatic (spread to other parts of the body);
- has a certain type of abnormal gene called “BRAF”
About 10 to 15 percent of people with colorectal cancer have the abnormal BRAF gene, which causes cancer cells to multiply out of control. Identifying whether a person with colorectal cancer has the BRAF gene is an important way to identify an appropriate treatment.
In addition to conducting a clinical trial focused on BRAF-positive colorectal cancer, we are also evaluating other approaches and potential treatments.
If you or a loved one are considering taking part in a colorectal cancer clinical trial, find more information below. With your participation, clinical research might help to identify better treatment options for people with colorectal cancer.